Abstract
No public abstract is available from the verified source records.
Amélie Anota, Sylvie Chabaud, Claire Cropet, Éric Pujade-Lauraine, Jean‐Emmanuel Kurtz, Isabelle Laure Ray-Coquard
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Re: Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
10.1093/jnci/djag212 · 2026
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
10.1056/nejmoa1911361 · 2019
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
10.1016/j.ygyno.2021.07.016 · 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
10.1016/s1470-2045(21)00098-x · 2021
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
10.1016/j.ygyno.2024.01.021 · 2024
A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
10.1200/jco.22.01003 · 2022
No additional external references are available.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%